A Phase 1b/2 Trial of Hu5F9-G4 in Combination With Rituximab or Rituximab + Chemotherapy in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 27 May 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Gemcitabine (Primary) ; Magrolimab (Primary) ; Oxaliplatin (Primary) ; Rituximab (Primary)
Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
Focus Adverse reactions; Proof of concept; Registrational; Therapeutic Use
Sponsors Forty Seven; Gilead Sciences

22 May 2024 Status changed from active, no longer recruiting to discontinued.
18 Dec 2023 Planned End Date changed from 1 Aug 2024 to 1 May 2024.
18 Dec 2023 Planned primary completion date changed from 1 Aug 2024 to 1 May 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com